M&A Deal Summary |
|
|---|---|
| Date | 2023-11-01 |
| Target | Denali Medpharma |
| Sector | Life Science |
| Buyer(s) | Resolian |
| Deal Type | Add-on Acquisition |
SEARCH BY
Resolian is a contract research organization (CRO) that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Resolian was founded in 2008 and is headquartered in Malvern, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: China M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-17 |
DDS
Fordham, United Kingdom DDS’s Bioanalytical solutions include liquid-chromatography mass spectrometry (LC-MS) and immunoassay bioanalysis, to provide data for pharmacokinetics, immunogenicity, pharmacodynamics, and cell-based assays supporting all phases of drug development to GCP and GLP standards. DDS is based in Fordham, United Kingdom. |
Buy | - |
